Biotech Values

[Summer2762]

There is also this possibility in case anyone missed it

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76766

--

IMO, the major issue in investing in OGXI at this moment is that we dont know how these approvals (of abi after (& before?) chemo & mdv3100 after chemo) will mess up the existing OGX trials, especially the SYNERGY trial, which is open label. Even though I trust TEVA, I am not sure if even TEVA can skirt around the interaction issues.

Otherwise, I don't share the other expressed concerns (there is no money/time/room for another drug, OGX-011 & 427 are antisense drugs or the chemo in mCRPC going away).